SalubrisBio
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Maryland, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
45 W Watkins Mill Rd Ste E, Gaithersburg...Website
www.salubrisbio.comRevenue
$8.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
1
About SalubrisBio
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing complex biologics for cardiovascular, oncology, and neurodegenerative diseases. SalubrisBio was founded in August 2016 as a wholly-owned subsidiary of the China-based pharmaceutical company Shenzhen Salubris Pharmaceuticals Co.Explore more
SalubrisBio Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SalubrisBio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on SalubrisBio recently announced quarterly report
Check if SalubrisBio has recently received funding, and reach out quickly before it becomes old news!
Click to see if SalubrisBio had a recent Job posting/layoffs
Product Launch: Get notified when SalubrisBio launches new products
Congratulate Masked Content for being promoted to Masked Content at SalubrisBio
Funding: Get notified immidiatlly once SalubrisBio has new funding data
SalubrisBio, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if SalubrisBio is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to SalubrisBio
Compare insights from companies similar to SalubrisBio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
SalubrisBio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
SalubrisBio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about SalubrisBio.
SalubrisBio financials insights
Gather financial insights about SalubrisBio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Other Financing Round
$32M
2023
Unspecified
$35M
2024
Other Financing Round
$35M
SalubrisBio Tech Stack
A closer look at the technologies used by SalubrisBio
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Hiring Plans
SalubrisBio has more open roles in Medical & Health than it has had at any time in the past 12 months. Areas of expertise include: Biomedical Sciences, Toxicology, Bioanalysis, Oncology, Protocol Analysis, Biomarkers, and Cardiovascular Biology.
Hiring Plans
Event
Product Marketing, Events, Business Intelligence, Engineering, Analytics & Insights, Research & Development, Sales, Search, Software, Bioengineering, Laboratory Operations, Clinical Operations, Field Marketing, Operations
Funding
Funding
SalubrisBio News & Media
Salubris Biotherapeutics Announces European Medicines Agency Approval to Initiate a Phase 1 Clinical Trial of JK06, a 5T4-Targeted ADC, in Solid Tumors
GAITHERSBURG, Md.--(BUSINESS WIRE)--Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced it has received approval from the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of JK06 in a basket of solid tumors known to express 5T4. 5T4 is an oncofetal protein that is overexpressed in a wide range of tumor types, including lung, breast, renal and genitourSalubris Biotherapeutics Announces $35 Million in Financing and Provides Pipeline Progress Update
GAITHERSBURG, Md.--(BUSINESS WIRE)--Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced a new capital infusion of $35 million to fund continued research and development of clinical and pre-clinical programs. SalubrisBio also provided progress updates for JK07, the first investigational antibody fusion protein for heart failure, JK08, the first investigational IL15-CTLA4Salubris Biotherapeutics Presents Positive Initial Data from Phase 1b/2 Clinical Trial of JK08 at the European Society for Medical Oncology Annual Congress 2023
GAITHERSBURG, Md.--(BUSINESS WIRE)--Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced that positive initial data from the first-in-human study evaluating JK08 in adults with solid tumors were presented in a poster session during the European Society of Medical Oncology Annual Congress 2023. The presentation included safety data from 32 patients with relapsed or refractSalubris Biotherapeutics Presents Positive 6-Month Data from Phase 1b Clinical Trial of JK07 in Late-Breaking Session at The Heart Failure Society of America Annual Meeting 2023
GAITHERSBURG, Md.--(BUSINESS WIRE)--Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced positive updated results from the completed Phase 1b study of JK07 in patients with HFrEF. The data were presented in a late breaking oral session during the Heart Failure Society of America Annual Scientific Meeting 2023. JK07 is the first investigational antibody fusion protein and
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding SalubrisBio
Sign Up For FreeTo access detailed company insights
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing complex biologics for cardiovascular, oncology, and neurodegenerative diseases. SalubrisBio was founded in August 2016 as a wholly-owned subsidiary of the China-based pharmaceutical company Shenzhen Salubris Pharmaceuticals Co.... Read More
